Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cognition Therapeutics Inc. Common Stock
CGTX | US
1.35
USD0.10
8.00%
CGTX | US
About Cognition Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
1.35
Open
1.34
High
1.39
Low
1.25
Cognition Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812 an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase New York.
View LessCGTX | US
Risk
79.9
Sharpe
3.30
Luna's Score
63/100
Recommendation
Hold
Luna says (CGTX | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
97.8%1 month
79.9%3 months
123.6%6 months
102.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.86
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
-0.44
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-58.61M
MarketCap
54.18M
MarketCap(USD)
54.18M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-108.31
Short ratio
1.04
Short perc.
1.91
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.34
Range1M
0.34
Range3M
0.84
Volumes: Market Activity
Rel. volume
2.89
Price X volume
3.90M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.44 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.86 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 123.61 | - | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 54.18M | - | Emerging |
